

TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED
(Formerly known as Tianjin Zhong Xin Pharmaceutical Group Corporation Limited)
(Company Registration No.: 91120000103100784F)
(Incorporated in the People's Republic of China)

RESOLUTIONS PASSED AT THE 6TH BOARD MEETING FOR FY2025

The board of directors (the “Board”) and every individual director of Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (formerly known as Tianjin Zhong Xin Pharmaceutical Group Corporation Limited) (the “Company”) hereby confirm that they will individually and collectively accept full responsibility for the accuracy of the information given in this announcement, and confirm, having made all reasonable enquiries, that to the best of their knowledge and belief, the facts stated in this announcement are fair and accurate in all material respects as at the date of this announcement, and that there are no material facts the omission of which would make any statement in this announcement misleading.

On 17 October 2025, the Company issued a notice of Board meeting to its directors (the “**Directors**”) convening the 6th Board meeting for the financial year ending 31 December 2025 (“**FY2025**”). The meeting was duly convened on 29 October 2025 via a combination of a physical meeting and teleconference. The said meeting was held in compliance with the applicable Company Law and Securities Law, as well as the Articles of Association of the Company. The following resolutions were duly passed by the Board, with the approval of all Directors:

1. That the full text and summary of the third quarter financial statement for FY2025 prepared in accordance with the accounting standards of the People's Republic of China (the “**PRC**”), and the third quarter interim financial report for FY2025 prepared in accordance with the International Financial Reporting Standards, be approved.

To the best of the knowledge of the Directors and management of the Company, there is no other information that would cause the contents of the aforesaid financial statements to be false or misleading.

Further information is set out in the Company's separate announcement on its third quarter results released on the same date as this announcement.

2. That the proposed contents of the “Amendments to the Articles of Association of the Company and application for changes in the industrial and commercial registration” (关于修订《公司章程》并办理工商变更的议案) be approved.
3. That the proposed re-appointment of CAC Certified Public Accountants LLP (中审华会计师事务所) as the PRC auditors of the Company for FY2025 to hold office until the conclusion of the next annual general meeting, and the proposed re-appointment of Foo Kon Tan LLP as the international auditors of the Company for FY2025 to hold office until the conclusion of the next annual general meeting, and to propose for the shareholders of the Company (“**Shareholders**”) at the general meeting to authorise the Board to determine their respective remuneration, be approved.
4. That the proposed declaration of an interim dividend for FY2025 be approved.

The Board has proposed to declare an interim dividend for FY2025 on the basis of RMB24.50 (inclusive of taxes) for every ten (10) shares in the capital of the Company (the “**Proposed Interim Dividend**”). The Proposed Interim Dividend is payable in respect of all issued shares in

the capital of the Company as at the record date to be determined by the Company for the purposes of determining Shareholders' entitlements to the Proposed Interim Dividend. Subject to the Proposed Interim Dividend being approved by Shareholders at the 2025 2nd EGM (as defined below), the Company will announce the record date and the payment date for the Proposed Interim Dividend in due course.

5. That the proposed adjustments to the Company's internal management structure be approved.

The Board has approved the Company's proposal to adjust its internal management structure as follows:

- (a) the establishment of a new department, the "Supply Chain Management Centre (供应链管理 中心)", at the Company's headquarters;
 - (b) the dissolution of the existing "Intelligent Manufacturing Centre (智能制造中心)" and "Medicinal Materials Resources Centre (药材资源中心)", with their respective functions to be integrated into the newly established Supply Chain Management Centre and the Company's Herbal Medicine Branch; and
 - (c) the dissolution of the existing "Product Planning Department (产品规划部)", with its functions to be integrated into the Product and Brand Development Department (产品与品牌发展部) of the Company's Health Technology Industry Development Branch.
6. That pursuant to the applicable Company Law and the Articles of Association of the Company, the proposed convening of the 2nd extraordinary general meeting of the Company in 2025 (the "2025 2nd EGM") be approved.

The resolutions referred to in paragraphs 2, 3 and 4 above shall be submitted for Shareholders' approval at the 2025 2nd EGM. A circular to Shareholders containing, *inter alia*, further information on the said resolutions, together with the notice of the 2025 2nd EGM, will be despatched to Shareholders in due course.

By Order of the Board

Jiao Yan
Secretary to the Board of Directors
30 October 2025